Santellano-Juárez B, González-Islas D, Contreras-Ramírez E, Orea-Tejeda A, Pineda-Juárez J, Peláez-Hernández V, Keirns-Davies C, Herrera-Saucedo R, Elizondo-Montes M, Pérez-Cortes G

Idioma: Ingles.
Referencias bibliográficas: 29
Paginas: 253-258
Archivo PDF: 168.53 Kb.

RESUMEN

Antecedentes: Los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) tienen alta prevalencia de insuficiencia cardíaca (IC). Los pacientes con concurrente IC y EPOC tienen peor pronóstico. Sin embargo, el impacto de la insuficiencia cardíaca derecha (ICD) sobre la mortalidad hospitalaria no ha sido explorada. Objetivos: Evaluar la asociación entre la ICD y la mortalidad hospitalaria en pacientes con EPOC. Métodos: Estudio transversal analítico llevado a cabo en pacientes con EPOC hospitalizados. Los pacientes hospitalizados entre el 2014 y 2015 fueron incluidos. Resultados: Noventa y cinco pacientes con diagnóstico de EPOC fueron analizados: EPOC solo (n = 25), EPOC con ICFEp (insuficiencia cardíaca con fracción de expulsión preservada) (n = 29), EPOC e IC (n = 41), y EPOC con ICFEc (insuficiencia cardíaca con fracción de expulsión reducida) (n = 0). Las variables asociadas con riesgo de mortalidad hospitalaria fueron ICD (OR: 10.91, 95% CI: 1.28 a 92.65, p = 0.029), evento cerebrovascular (OR: 14.4, 95% CI: 2.64 a 78.37, p 0.002), tromboembolia pulmonar (OR: 2.09, 95% CI: 2.09 1.47-2.98 ‹ 0.001) y enfermedad renal crónica (OR: 4.08, 95% CI: 3.36 a 7.01, p ‹ 0.001). Conclusión: La ICD es un factor de riesgo independiente para mortalidad hospitalaria en los pacientes con EPOC, que incrementa 9.42 veces.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498-504.

2. Lindberg A, Jonsson AC, Rönmark E, Lundgren R, Larsson LG, Lundbäck B. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor’s diagnosis, symptoms, age, gender, and smoking habits. Respiration 2005;72(5):471-479.

3. Rosenberg SR, Kalhan R, Mannino DM. Epidemiology of Chronic Obstructive Pulmonary Disease: Prevalence, morbidity, mortality, and risk factors. Semin Respir Crit Care Med 2015;36(4):457-469. doi: 10.1055/s-0035-1555607.

4. Menezes AMB, Perez-Padilla R, Jardim JRB, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005;366(9500):1875-1881.

5. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005;128(4):2005-2011.

6. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012;186(10):975-981. doi: 10.1164/rccm.201207-1299OC

7. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124(2):459-467.

8. Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 2008;101(3):353-358. doi: 10.1016/j.amjcard.2007.08.046.

9. Divo M, Cote C, de Torres JP, et al.; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186(2):155-161. doi: 10.1164/rccm.201201-0034OC.

10. Divo MJ, Casanova C, Marin JM, et al.; BODE Collaborative Group. COPD comorbidities network. Eur Respir J 2015;46(3):640-650. doi: 10.1183/09031936.00171614.

11. Djoussé L, Driver JA, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA 2009;302(4):394-400. doi: 10.1001/jama.2009.1062.

12. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008;101(7):1016-1022. doi: 10.1016/j.amjcard.2007.11.061.

13. Buist AS, McBurnie MA, Vollmer WM, et al.; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370(9589):741-750.

14. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 2013;34(36):2795-2803. doi: 10.1093/eurheartj/eht192.

15. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J 2012;39(1):51-58. doi: 10.1183/09031936.00044411.

16. Boschetto P, Fucili A, Stendardo M, et al. Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. Respirology 2013;18(1):125-130. doi: 10.1111/j.1440-1843.2012.02264.x.

17. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11(2):130-139. doi: 10.1093/eurjhf/hfn013.

18. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187(4):347-365. doi: 10.1164/rccm.201204-0596PP.

19. McMurray JJ, Adamopoulos S, Anker SD, et al.; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14(8):803-869. doi: 10.1093/eurjhf/hfs105.

20. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370(9589):797-799.

21. Fisher KA, Stefan MS, Darling C, Lessard D, Goldberg RJ. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study. Chest 2015;147(3):637-645. doi: 10.1378/chest.14-0607.

22. Yoshihisa A, Takiguchi M, Shimizu T, et al. Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol 2014;64(4):256-264. doi: 10.1016/j.jjcc.2014.02.003.

23. Boudestein LCM, Rutten FH, Cramer MJ, Lammers JWJ, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009;11(12):1182-1188. doi: 10.1093/eurjhf/hfp148.

24. Kwon BJ, Kim DB, Jang SW, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail 2010;12(12):1339-1344. doi: 10.1093/eurjhf/hfq157.

25. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135-1143.

26. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007;29(3):527-534.

27. Patel AR, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188(9):1091-1099. doi: 10.1164/rccm.201306-1170OC.

28. Chang C, Yao W. Time course of inflammation resolution in patients with frequent exacerbations of chronic obstructive pulmonary disease. Med Sci Monit 2014;20:311-320. doi: 10.12659/MSM.889828.

29. Orea-Tejeda A, Bozada-Gutiérrez KE, González-Islas D, et al. Right heart failure as a risk factor for cerebrovascular event in patients with chronic obstructive pulmonary disease. Global Heart 2016;11(Suppl 2):e44.